Artificial intelligence predicts genetics of cancerous brain tumors in under 90 seconds

Researchers hope it will improve diagnosis and treatment, as well as clinical trial enrollment

12:00 PM

Author | Noah Fromson

cancer cell
Jacob Dwyer, Justine Ross, Michigan Medicine

Using artificial intelligence, researchers have discovered how to screen for genetic mutations in cancerous brain tumors in under 90 seconds — and possibly streamline the diagnosis and treatment of gliomas, a study suggests.

A team of neurosurgeons and engineers at Michigan Medicine, in collaboration with investigators from New York University, University of California, San Francisco and others, developed an AI-based diagnostic screening system called DeepGlioma that uses rapid imaging to analyze tumor specimens taken during an operation and detect genetic mutations more rapidly.

In a study of more than 150 patients with diffuse glioma, the most common and deadly primary brain tumor, the newly developed system identified mutations used by the World Health Organization to define molecular subgroups of the condition with an average accuracy over 90%. The results are published in Nature Medicine.

“This AI-based tool has the potential to improve the access and speed of diagnosis and care of patients with deadly brain tumors,” said lead author and creator of DeepGlioma Todd Hollon, M.D., a neurosurgeon at University of Michigan Health and assistant professor of neurosurgery at U-M Medical School.

Molecular classification is increasingly central to the diagnosis and treatment of gliomas, as the benefits and risks of surgery vary among brain tumor patients depending on their genetic makeup. In fact, patients with a specific type of diffuse glioma called astrocytomas can gain an average of five years with complete tumor removal compared to other diffuse glioma subtypes.

DeepGlioma creates an avenue for accurate and more timely identification that would give providers a better chance to define treatments and predict patient prognosis."

Todd Hollon, M.D.

 

However, access to molecular testing for diffuse glioma is limited and not uniformly available at centers that treat patients with brain tumors. When it is available, Hollon says, the turnaround time for results can take days, even weeks.

“Barriers to molecular diagnosis can result in suboptimal care for patients with brain tumors, complicating surgical decision-making and selection of chemoradiation regimens,” Hollon said.

Prior to DeepGlioma, surgeons did not have a method to differentiate diffuse gliomas during surgery. An idea that started in 2019, the system combines deep neural networks with an optical imaging method known as stimulated Raman histology, which was also developed at U-M, to image brain tumor tissue in real time.

SEE ALSO: Artificial Intelligence Improves Brain Tumor Diagnosis (michiganmedicine.org)

“DeepGlioma creates an avenue for accurate and more timely identification that would give providers a better chance to define treatments and predict patient prognosis,” Hollon said.

Even with optimal standard-of-care treatment, patients with diffuse glioma face limited treatment options. The median survival time for patients with malignant diffuse gliomas is only 18 months.

While the development of medications to treat the tumors is essential, fewer than 10% of patients with glioma are enrolled in clinical trials, which often limit participation by molecular subgroups. Researchers hope that DeepGlioma can be a catalyst for early trial enrollment. 

Progress in the treatment of the most deadly brain tumors has been limited in the past decades- in part because it has been hard to identify the patients who would benefit most from targeted therapies,” said senior author Daniel Orringer, M.D., an associate professor of neurosurgery and pathology at NYU Grossman School of Medicine, who developed stimulated Raman histology. “Rapid methods for molecular classification hold great promise for rethinking clinical trial design and bringing new therapies to patients.”

Additional authors include Cheng Jiang, Asadur Chowdury, Akhil Kondepudi, Arjun Adapa, Wajd Al-Holou, Jason Heth, Oren Sagher, Maria Castro, Sandra Camelo-Piragua, Honglak Lee, all of University of Michigan, Mustafa Nasir-Moin, John Golfinos, Matija Snuderl, all of New York University, Alexander Aabedi, Pedro Lowenstein, Mitchel Berger, Shawn Hervey-Jumper, all of University of California, San Francisco, Lisa Irina Wadiura, Georg Widhalm, both of Medical University Vienna, Volker Neuschmelting, David Reinecke, Niklas von Spreckelsen, all of University Hospital Cologne, and Christian Freudiger, Invenio Imaging, Inc.

This work was supported by the National Institutes of Health, Cook Family Brain Tumor Research Fund, the Mark Trauner Brain Research Fund, the Zenkel Family Foundation, Ian’s Friends Foundation and the UM Precision Health Investigators Awards grant program.

Paper cited: “Artificial-intelligence-based molecular classification of diffuse gliomas using rapid, label-free optical imaging,” Nature Medicine. DOI: 10.1038/s41591-023-02252-4


More Articles About: Cancer (Oncology) Cancer Research All Research Topics Basic Science and Laboratory Research Future Think Brain Tumors Neurological (Brain) Conditions Cancer: Help, Diagnosis & Treatment Cancer Treatment Emerging Technologies
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories two men together walking outside
Health Lab
Exercise can reduce your cancer risk and help prevent its return
A director of exercise and health behavior in oncology shares ways to help cancer survivors live longer and better lives by incorporating exercise and other physical activity into everyday routines.
Health Lab Podcast in brackets with a background with a dark blue translucent layers over cells
Health Lab Podcast
Using biolasers to improve cancer diagnostic tools
Lighting up cancer cells with biolasers. The technique overcomes the limitations of current cancer diagnostic tools. For more on this story and for others like it, visit the Health Lab website where you can subscribe to our Health Lab newsletters to receive the latest in health research and information to your inbox each week. Health Lab is a part of the Michigan Medicine Podcast Network, and is produced by the Michigan Medicine Department of Communication. You can subscribe to Health Lab on Apple Podcasts, Spotify, or wherever you listen to podcasts.
outline of a child and dna floating around purple shadowing some dark navy
Health Lab
Researchers tackle rare, aggressive tumors in children
ATRT are rare, aggressive tumors. A lot of research has been done in identifying their cause and there are good therapies available. However, more research needs to be done. This is a Q&A article to raise awareness about ATRT and highlight the current research.
paperwork with white and blue and red and says medicare john smith hospital part a medical part b 09-01 09-0
Health Lab
How did health insurance coverage changes affect older adults?
Two University of Michigan studies show how past policy decisions have affected older Americans with modest or low incomes.
News Release
Eight U-M researchers win PECASE awards
Three U-M medical researchers, and five others from the U-M faculty, have received one of the nation's top honors for scientists and engineers, as announced by the White House.
person talking to older couple on couch in living room
Health Lab
85% of Mexican Americans with dementia unaware of diagnosis, outpacing overall rate
More than three-quarters of older adults with dementia may be unaware of their diagnosis, a University of Michigan study finds.